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We formulated an ultra-small, gadolinium-based nanoparticle (AGuIX) with theranostic properties to
simultaneously enhance MRI tumor delineation and radiosensitization in a glioma model. The 9L glioma
cells were orthotopically implanted in 10-week-old Fischer rats. The intra-tumoral accumulation of
AGuIX was quantified using MRI T1-maps. Rats randomized to intervention cohorts were subsequently
treated with daily temozolomide for five consecutive days before radiotherapy treatment. Collectively,
a series of 32 rats were divided into untreated (n = 7), temozolomide-only (n = 7), temozolomide and
MRT (n = 9), AGuIX and MRT (n = 7), and triple therapy (temozolomide, AGuIX NPs, and MRT; n = 9)
cohorts. AGuIX nanoparticles achieved a maximum intra-tumoral concentration (expressed as concentra-
tion of Gd3+) at 1 h after intravenous injection, reaching a mean of 227.9 ± 60 lM. This was compared to
concentrations of 10.5 ± 9.2 lM and 62.9 ± 24.7 lM in the contralateral hemisphere and cheek, respec-
tively. There was a slower washout in the intra-tumor region, with sustained tumor-to-contralateral ratio
of AGuIX, up to 14-fold, for each time point. The combination of AGuIX or temozolomide with MRT
improved the median survival time (40 days) compared to the MeST of control rats (25 days)
(p < 0.002). There was a trend towards further increased survival when the three treatments were com-
bined (MeST of 46 days). This study demonstrated the selective accumulation of AGuIX in high grade
glioma, as well as the potential survival benefits when combined with chemoradiation.1. Introduction
Glioblastoma multiforme (GBM) is the most common and
aggressive form of high-grade glioma with 3 per 100,000 new cases
per year and a median survival of 14 months, despite optimal sur-
gical resection followed by postoperative radiotherapy and
chemotherapy. Tumor almost invariably recurs at its original site,
leading to a median survival of 1 year after diagnosis, and a
5-year survival rate of 9.8% [1]. The effect of radiation therapy
(RT) on survival has been demonstrated in GBM patients treatedwith whole brain RT, although not without side effects. Further
benefit has also not been seen from dose escalation [2,3]. Thus,
new protocols aiming to maximize radiation potency to targeted
tissue is paramount.
Radiation sensitizers are compounds that are given concur-
rently with RT in an effort to increase local therapeutic effect. Sev-
eral classes of radiosensitizers have been studied but none have
been approved for high grade gliomas [4].We have developed a
new class of ultrasmall, theranostic (3.0 ± 1.0 nm size) gadolinium
(Gd)-based nanoparticle (AGuIX NPs) for theranostic applications,
to improve radiographic delineation and increase the intra-
tumoral dose–effect delivered by the particles beams [5–8]. High
Z-elements are incorporated to enhance local radiation absorption
and introduce harmful photons, photoelectrons, Auger electrons,glioma
2 S. Dufort et al. / Journal of Clinical Neuroscience xxx (xxxx) xxxCompton electrons and radical species [9]. The effect is a more effi-
cient destruction of the tumor, without dose escalation to healthy
tissue. Studies have demonstrated such efficacy when combining
AGuIX NPs with radiation for glioblastoma [10,11], lung tumors
[12], pancreatic adenocarcinoma [13,14], and multifocal intracra-
nial melanoma metastases [15].
AGuIX NPs can also be used for MRI tumor delineation [16,17].
They are characterized by rapid clearance by normal tissue, high
tumor-to-healthy tissue affinity ratios, and extravasation from nor-
mal blood vessels based on enhanced permeability and retention
(EPR) effect [18–23]. Our nanotechnology showed superior con-
trast compared to other Gd chelates [24].
In this study, we aimed to quantify local AGuIX concentration in
orthotopic glioma rat tumor after intravenous injection and to
examine its synergistic effects on survival from combinations of
temozolomide, AGuIX NPs and radiotherapy in the treatment of
high-grade gliomas.2. Materials and methods
2.1. Gadolinium (Gd)-based AGuIX NPs
The Gd-based AGuIX NPs were synthesized and characterized
according to a previously described protocol [16,25]. Briefly, the
NPs are synthesized through a top-down process and are made
of Gd chelates (1,4,7,10-tetraazacyclododecane-1-glutaric acid-
4,7,10-triacetic acid, i.e. DOTAGA) covalently linked to a polysilox-
ane network core. During synthesis, pH was adjusted to 7.2 ± 0.15
and the final hydrodynamic diameter was precisely controlled to
reach 3 ± 1 nm, favoring renal elimination. The r1 value used for
the MRI calculation was equal to 6 mM1.s1 (7 T), while the
r2/r1 ratio is 2.2 (7 T) (compared with 1.14 at 1.4 T) [16]. More than
90% of the injected NPs is renally cleared within the first day after
injection, allowing a safe elimination [26].3. Treatment and irradiation procedures
3.1. Animals
All procedures related to animal care conformed to the Guideli-
nes of the European and French Government with licenses 380,325
and B3818510002, and were approved by the Ethical Committee ofFig. 1. Diagram of the therapeu
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French Ministry of Research.
3.2. Brain tumor inoculation
The 9L glioma (9LGS) cells were implanted in the brain of male
10-week-old Fisher 344 rats (Charles River, France) [27,28]. Anes-
thetized animals were placed on a stereotactic frame, and 104
9LGS cells suspended in 1 mL DMEM + 1% penicillin/streptomycin
were pushed manually within 30 s using a Hamilton syringe
inserted into the right caudate nucleus (3.5 mm lateral to the
bregma, 6 mm depth below the skull surface). All time intervals
stated in the manuscript are post implantation, i.e. D10 means
10 days after tumor implantation.
The rats were anesthetized by inhalation of 4% isoflurane in air
followed by an intraperitoneal injection of xylazine/ketamine
64.5/5.4 mg.kg1 for the glioma implantation, nanoparticle injec-
tion and irradiation. The rats were anesthetized by inhalation of
2.5% isoflurane in air for MRI examination. In any case, the eyes
of the animals were embedded with a drop of Ocry-gel (TVM Lab-
oratories, France) during the anesthesia to avoid dryness of the
cornea.
3.3. Treatments
The AGuIX NPs were injected in the saphenous vein with either
1 mL of 100 g/L AGuIX NPs in saline buffer for MRI examination or
1.4 mL of 40 g/L for therapy. Temozolomide was delivered by
intraperitoneal injection (1 mL containing 3.3 mg of temozolo-
mide) for 5 consecutive days, from day 6 to 10 after tumor implan-
tation. The AGuIX NPs were intravenously injected at day 10, 4 h
before Microbeam Radiation Therapy (MRT) (Fig. 1). Animal weight
was monitored daily during the 5 days of treatment with temo-
zolomide, then weekly.
3.4. MRI acquisitions
MRI was performed on a 7 T scanner (Biospec 70/20, Bruker
Avance III console, Germany – Grenoble MRI facility IRMaGE)
equipped with a 660 mT/m gradient coil and volume transmit/sur-
face receive radiofrequency coils. Animals were placed in the prone
position. All images were acquired in the coronal orientation. The
MRI protocol was composed of three sequences:tic experimental protocol.
eranostic gadolinium-based nanoparticles improve high-grade rat glioma
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Echoes (RARE) images (repetition time (TR)/effective echo time
(TE) 2500/40 ms, number of average (NA) = 2, slice thick-
ness = 1 mm, reconstruction voxel size = 117  117  1000 lm,
field of view (FOV) = 3  3 cm) were used for tumor localization
and evaluation of the tumor volume;
– T1-weighted spin-echo images (TR/TE 800/5 ms, NA = 4, slice
thickness = 1 mm, reconstruction voxel size = 234  234 
1000 lm, FOV = 3  3 cm) were acquired to assess the spatial
extent of the extravasation of the contrast agent;
– T1 maps (inversion recovery obtained with spin-echo planar
imaging (EPI) sequence and 18 inversion times values in the
range [35–7200] ms, TR/ TE = 18,000/20 ms, NA = 1, slice thick-
ness = 1 mm, reconstruction voxel size = 234  234  1000 lm,
FOV = 3  3 cm) were used to estimate the concentration in NPs
in the tumor region.
The images from the three sequences were obtained from the
same imaging locations.
First, a preliminary study was performed over three rats at D14
stage to confirm tumor maturity on MRI and to quantify AGuIX NPs
in brain tumor, the contralateral hemisphere and the cheek mus-
cles [27]. The rats were imaged as previously described before
injection and at 1, 4, 7 and 24 h after injection of AGuIX NPs.
3.5. MRI data processing & analysis
MRI data were processed using homemade software developed
in MATLAB (MathWorks Inc., Natick, MA, USA) to calculate concen-
tration and create regions of interest (ROIs). For each MR image,
ROIs were manually delineated in the tumor, contralateral brain
and cheek muscle to measure the average signal. The ROIs defined
on the T2-weighted images were then extended to the others MRI
sequences (T1-weighted and T1 map images).
3.6. AGuIX concentration
The T1 maps were obtained by fitting, pixel by pixel, the inver-
sion recovery data with a 3-parameter, exponential recovery,
model [29]. The concentration of Gd3+ was calculated using the
relaxation time determined on the T1 maps, according to the
formula
Gd3þ
h i
¼ 1
r1
1
T1 tð Þ 
1
T1 t0ð Þ
 
where T1 (t0) is the relaxation time before AGuIX injection (in sec-
onds), T1 (t) is the relaxation time after injection, and r1 is the relax-
ivity per Gd3+ in AGuIX NPs at 7 T (6 mM1.s1) [16].
3.7. Radiation source and microbeam radiation therapy (MRT) setup
Irradiations were performed at the ID17 Biomedical Beamline of
the European Synchrotron Radiation Facility (Grenoble, France)
using X-rays emitted tangentially from electron bunches circulat-
ing in a storage ring. The wiggler source produces a white spec-
trum of photons which extends after filtration (Be (0.5 mm), C
(1.5 mm), Al (1.5 mm) and Cu (1.0 mm)) from 50 to 350 keV (mean
energy of 90 keV). The quasi-laminar beam is spatially fractionated
into an array of microbeams by using an adjustable multislit colli-
mator positioned 41.7 m from the photon source and 100 cm
upstream from the head of the animals. Upstream from the multi-
slit collimator, the dose rate within a homogenous field of
10 mm  10 mm was approximately 90 Gy s1.mA1. Downstream
the multislit collimator, the peak entrance dose within the
microbeam was targeted for 72 Gy s1.mA1.Please cite this article as: S. Dufort, G. Appelboom, C. Verry et al., Ultrasmall th
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Ten days after tumor inoculation, the animals were positioned
prone on a Kappa-type goniometer (Huber, Germany) in front of
the X-rays source, on a home-made Plexiglas frame, and the align-
ment into the beam was performed using live cameras. The con-
tention of the rats was performed by a teeth bar, while animals
were under anesthesia. They received a lateral irradiation, from
their anatomically right side to their left. Then, a 90 angle was
applied to the motorized goniometer and the second irradiation
was performed in the anatomically anteroposterior direction. The
field of irradiation was fixed at 10.5 mm height and 8 mm wide
and was centered at the theoretical center of the tumor (i.e.
3.5 mm lateral to the bregma, 6 mm deep from the skull in the right
hemisphere). The microbeams were 50 mmwide with an on-center
distance fixed at 211 mm. The total irradiation procedure lasted
about 2 min. Animal immobility during exposure was checked on
three control video screens located in the control hutch. A series
of 32 rats was divided into untreated rats (n = 7), temozolomide-
treated rats (n = 7), temozolomide and MRT-treated rats (n = 9),
AGuIX NP and MRT-treated rats (n = 7), and triple therapy-treated
(temozolomide, AGuIX NP, and MRT) rats (n = 9). A 4 h interval
was required between NP injection and MRT based on results in
previous studies [10,30]. The spatial configuration of the microbe-
ams was checked by radiochromic films (Gafchromic, HD-810).
3.9. Survival analysis
The rats were followed up at the animal facility after the irradi-
ation. At a later tumor stage, rats were euthanized by intra-cardiac
injection of pentobarbital sodiumwithin the day before their antic-
ipated death as judged by clinical signs. Some of them were found
dead. The time between implantation and death was recorded as
survival time (one day was added for euthanized rats). The sur-
vivals of animals were represented on Kaplan-Meier curves and
compared using the log-rank test, and the Median Survival Time
(MeST) post-implantation was calculated. The increase in lifespan
in percent (ILS) characterizes the difference between median sur-
vival time for treated and untreated rats divided by the median
survival time for untreated rats.
4. Results
4.1. Distribution and quantification of AGuIX NPs in brain tumors
Qualitative visualization on T1-weighted MRI follow-up of the
AGuIX NPs distribution in 9L-glioma bearing rats identified very
strong contrast enhancement within engrafted tumor by the first
time-point, 1 h after the IV injection. No signal was seen before
AGuIX NPs administration. Tumor enhancement remained entirely
visible up to 24 h after administration, while the NPs were almost
completely eliminated from the contralateral brain region (Fig. 2A),
and was significantly greater than all comparative controls
(p < 0.01). Following this period, tumor contrast gradually
declined, implying AGuIX NP clearance.
The quantification of actual Gd contained in administered
AGuIX NPs, and the calculated Gd concentration obtained from
T1 maps, matched the qualitative image analysis (Fig. 2B). Maximal
intra-tumoral Gd concentration, reached a mean 227.9 ± 60 lM at
1 h after injection, and measured 65.2 ± 23.2 lM, 29.8 ± 8.3 lM
and 15.1 ± 0.9 lM, at 4 h, 7 h and 24 h respectively (Fig. 2C). Gd
concentration was noted to decrease in the contralateral brain
and cheek muscle, consistently with slower washout. Tumor-to-
contralateral hemisphere (T/C) ratio of AGuIX concentrations
achieved reached 21.6 at 1 h after administration and remained
up to 14-fold higher for each time point.eranostic gadolinium-based nanoparticles improve high-grade rat glioma
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Fig. 2. AGuIX distribution and quantification in 9L-glioma-bearing rats. (A) The T1-weighted MR images were acquired before and 1, 4, 7 and 24 h after intravenous injection
of 1 mL of AGuIX NPs ([AGuIX] = 100 g/L) over three rats at D14. The pictures indicate a tumor-T1 contrast enhancement due to the AGuIX NPs, until 24 h post intravenous
injection. (B) The Gd concentration maps were calculated from T1 maps acquired before and 1, 4, 7 and 24 h after IV injection of AGuIX NPs. The relative Gd concentration in
tumor was expressed as a Tumor-to-Contralateral (T/C) ratio. (C) Bar graph displaying gadolinium concentrations expressed as the means ± standard deviation (n = 3) in the
tumor and contralateral regions.
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temozolomide and radiation therapy for the management of brain
tumors
The radiosensitizing efficacy of the NPs combined with radia-
tion therapy was already demonstrated in the 9L-glioma-rat model
[10,11,24,30]. When further evaluating the therapeutic potential of
AGuIX NPs, we saw that a combination of AGuIX or temozolomide
with MRT improved the median survival time (40 days) compared
to the MeST of control rats (25 days) (p < 0.002). The increase of
survival further demonstrated a trend towards improved survival
when the three treatments were combined such that MeST was
46 days, compared to AGuIX + MRT and temozolomide + MRT
respectively (p = 0.1 and 0.137; Fig. 3).Fig. 3. Survival curve comparison obtained on 9L-glioma bearing rats.5. Discussion
Since the publication of the EORTC trial, several pharmacologi-
cal strategies have been tested with the objective of modulating
tumor radiosensitivity and enhancing radiotherapy. To date, only
marginal or non-existent clinical benefits have been obtained over
standard strategy. Two randomized trials, have failed to enhance
tumor control and survival in patients treated with radiation dose
escalation (60 Gy followed by a 10 Gy tumor boost) [2,3]. Similarly,
most radiosensitization by molecularly targeted agents is notPlease cite this article as: S. Dufort, G. Appelboom, C. Verry et al., Ultrasmall th
survival, Journal of Clinical Neuroscience, https://doi.org/10.1016/j.jocn.2019.0specific to tumor cells, and the toxicity to normal tissues remains
a limitation to these pharmacological strategies.
Here, we confirmed our ability to create both a therapeutic (sur-
vival enhancing) and diagnostic (tumor delineating) nanoparticle
that can easily be injected intravenously. Our data suggest the
selective accumulation of AGuIX NPs in brain tumors can provide
a 15% survival improvement over the standard temozolomide
and radiation regimen. It has been shown that ionizing radiation
not only disrupts tumor cells, but also induces a combination oferanostic gadolinium-based nanoparticles improve high-grade rat glioma
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brain barrier, neuroglial cells, and local inflammation [31–34].
Thus, we hypothesize that AGuIX NPs enhances ionizing radiation’s
tumoricidal properties locally but will also act as a chemotherapy
enhancer through blood brain barrier and angiogenesis disruption.
Technological advances have allowed the emergence of high
precision radiotherapy with the integration of 3D imaging.
Gadolinium is already a well-studied and incorporated heavy atom
for biomedical and therapeutic applications [10,14,35–37]. In some
of our previous work, AGuIX was compared to FDA-approved
gadolinium chelates and demonstrated a higher uptake and reten-
tion time by tumors allowing better contrast properties [30,35].
Based on these properties, AGuIX may allow for a more precise
tumor delineation on MRI via a passive accumulation within the
tumor due to the EPR effect. Such volume targeting is perhaps par-
ticularly important to promote local tumor control by irradiative
effects that are not achievable by external beam-dose escalation
alone or without introducing toxicities to normal tissue [2,3,10,30].
In conclusion, in this study we confirm that AGuIX NPs selec-
tively accumulate in glioma, and may have a potentiating effect
on survival when administered with standard of care temozolo-
mide and radiotherapy.Sources of support
This project was supported by Nano-H S.A.S. and the French
National Research Agency [grant numbers ANR-11-NANO-017
TheraGuIMA, ANR-12-RPIB-0010 MULTIMAGE]. The Grenoble
MRI facility IRMaGE was supported by the French program
‘‘Investissement d’Avenir” run by the ‘‘Agence Nationale pour la
Recherche” [grant number ANR-11-INBS-0006].
Authors F. Lux and O. Tillement are authors of patent
WO2011/135101. G. Le Duc and O. Tillement are authors of patent
WO2009/053644. These patents protect the nanoparticles
described in this publication: AGuIX. S. Dufort is an employee from
Nano-H S.A.S. that is developing AGuIX. S. Dufort and G. Le Duc are
employees from NH TherAguix S.A.S. that is evaluating the clinical
applications of AGuIX.Appendix A. Supplementary data
Supplementary data to this article can be found online at
https://doi.org/10.1016/j.jocn.2019.05.065.References
[1] Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al.
Effects of radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised phase III
study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459–66.
[2] Chang CH, Horton J, Schoenfeld D, Salazer O, Perez-Tamayo R, Kramer S, et al.
Comparison of postoperative radiotherapy and combined postoperative
radiotherapy and chemotherapy in the multidisciplinary management of
malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern
Cooperative Oncology Group study. Cancer 1983;52:997–1007.
[3] Nelson DF, Diener-West M, Horton J, Chang CH, Schoenfeld D, Nelson JS.
Combined modality approach to treatment of malignant gliomas–re-
evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint
study of the Radiation Therapy Oncology Group and the Eastern Cooperative
Oncology Group. NCI Monogr 1988:279–84.
[4] Stupp R, van den Bent MJ, Hegi ME. Optimal role of temozolomide in the
treatment of malignant gliomas. Curr Neurol Neurosci Rep 2005;5:198–206.
[5] Brauer-Krisch E, Serduc R, Siegbahn EA, Le Duc G, Prezado Y, Bravin A, et al.
Effects of pulsed, spatially fractionated, microscopic synchrotron X-ray beams
on normal and tumoral brain tissue. Mutat Res 2010;704:160–6.
[6] Kobayashi K, Usami N, Porcel E, Lacombe S, Le Sech C. Enhancement of
radiation effect by heavy elements. Mutat Res 2010;704:123–31.
[7] McMahon SJ, Mendenhall MH, Jain S, Currell F. Radiotherapy in the presence of
contrast agents: a general figure of merit and its application to gold
nanoparticles. Phys Med Biol 2008;53:5635–51.Please cite this article as: S. Dufort, G. Appelboom, C. Verry et al., Ultrasmall th
survival, Journal of Clinical Neuroscience, https://doi.org/10.1016/j.jocn.2019.0[8] Pradhan AK, Nahar SN, Montenegro M, Yu Y, Zhang HL, Sur C, et al. Resonant X-
ray enhancement of the Auger effect in high-Z atoms, molecules, and
nanoparticles: potential biomedical applications. J Phys Chem A
2009;113:12356–63.
[9] McMahon SJ, Hyland WB, Muir MF, Coulter JA, Jain S, Butterworth KT, et al.
Biological consequences of nanoscale energy deposition near irradiated heavy
atom nanoparticles. Sci Rep 2011;1:18.
[10] Le Duc G, Miladi I, Alric C, Mowat P, Brauer-Krisch E, Bouchet A, et al. Toward
an image-guided microbeam radiation therapy using gadolinium-based
nanoparticles. ACS Nano 2011;5:9566–74.
[11] Verry C, Dufort S, Barbier EL, Montigon O, Peoc’h M, Chartier P, et al. MRI-
guided clinical 6-MV radiosensitization of glioma using a unique gadolinium-
based nanoparticles injection. Nanomedicine (Lond) 2016.
[12] Dufort S, Bianchi A, Henry M, Lux F, Le Duc G, Josserand V, et al. Nebulized
gadolinium-based nanoparticles: a theranostic approach for lung tumor
imaging and radiosensitization. Small 2015;11:215–21.
[13] Detappe A, Kunjachan S, Rottmann J, Robar J, Tsiamas P, Korideck H, et al.
AGuIX nanoparticles as a promising platform for image-guided radiation
therapy. Cancer Nanotechnol 2015;6:4.
[14] Detappe A, Kunjachan S, Sancey L, Motto-Ros V, Biancur D, Drane P, et al.
Advanced multimodal nanoparticles delay tumor progression with clinical
radiation therapy. J Control Release 2016;238:103–13.
[15] Kotb S, Detappe A, Lux F, Appaix F, Barbier EL, Tran V-L, et al. Gadolinium-
based nanoparticles and radiation therapy for multiple brain melanoma
metastases: proof of concept before phase I trial. Theranostics 2016;6:418–27.
[16] Lux F, Mignot A, Mowat P, Louis C, Dufort S, Bernhard C, et al. Ultrasmall rigid
particles as multimodal probes for medical applications. Angew Chem Int Ed
Engl 2011;50:12299–303.
[17] Sancey L, Lux F, Kotb S, Roux S, Dufort S, Bianchi A, et al. The use of theranostic
gadolinium-based nanoprobes to improve radiotherapy efficacy. Br J Radiol
2014;87:20140134.
[18] Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev
Cancer 2003;3:401–10.
[19] Iyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced permeability and
retention effect for tumor targeting. Drug Discov Today 2006;11:812–8.
[20] Jang SH, Wientjes MG, Lu D, Au JL. Drug delivery and transport to solid tumors.
Pharm Res 2003;20:1337–50.
[21] Maeda H, Sawa T, Konno T. Mechanism of tumor-targeted delivery of
macromolecular drugs, including the EPR effect in solid tumor and clinical
overview of the prototype polymeric drug SMANCS. J Control Release
2001;74:47–61.
[22] Noguchi Y, Wu J, Duncan R, Strohalm J, Ulbrich K, Akaike T, et al. Early phase
tumor accumulation of macromolecules: a great difference in clearance rate
between tumor and normal tissues. Jpn J Cancer Res 1998;89:307–14.
[23] Seymour LW, Miyamoto Y, Maeda H, Brereton M, Strohalm J, Ulbrich K, et al.
Influence of molecular weight on passive tumour accumulation of a soluble
macromolecular drug carrier. Eur J Cancer 1995;31A:766–70.
[24] Le Duc G, Roux S, Paruta-Tuarez A, Dufort S, Brauer E, Marais A, et al.
Advantages of gadolinium based ultrasmall nanoparticles vs molecular
gadolinium chelates for radiotherapy guided by MRI for glioma treatment.
Cancer Nanotechnol 2014;5:4.
[25] Mignot A, Truillet C, Lux F, Sancey L, Louis C, Denat F, et al. A top-down
synthesis route to ultrasmall multifunctional Gd-based silica nanoparticles for
theranostic applications. Chemistry 2013;19:6122–36.
[26] Sancey L, Kotb S, Truillet C, Appaix F, Marais A, Thomas E, et al. Long-term
in vivo clearance of gadolinium-based AGuIX nanoparticles and their
biocompatibility after systemic injection. ACS Nano 2015;9:2477–88.
[27] Bouchet A, Bidart M, Miladi I, Le Clec’h C, Serduc R, Coutton C, et al.
Characterization of the 9L gliosarcoma implanted in the Fischer rat: an
orthotopic model for a grade IV brain tumor. Tumour Biol 2014;35:6221–33.
[28] Benda P, Someda K, Messer J, Sweet WH. Morphological and immunochemical
studies of rat glial tumors and clonal strains propagated in culture. J Neurosurg
1971;34:310–23.
[29] Barbier EL, Liu L, Grillon E, Payen JF, Lebas JF, Segebarth C, et al. Focal brain
ischemia in rat: acute changes in brain tissue T1 reflect acute increase in brain
tissue water content. NMR Biomed 2005;18:499–506.
[30] Dufort S, Le Duc G, Salome M, Bentivegna V, Sancey L, Brauer-Krisch E, et al.
The high radiosensitizing efficiency of a trace of gadolinium-based
nanoparticles in tumors. Sci Rep 2016;6:29678.
[31] Belka C, Budach W, Kortmann RD, Bamberg M. Radiation induced CNS
toxicity–molecular and cellular mechanisms. Br J Cancer 2001;85:1233–9.
[32] Kolesnick R, Fuks Z. Radiation and ceramide-induced apoptosis. Oncogene
2003;22:5897–906.
[33] Nordal RA, Wong CS. Molecular targets in radiation-induced blood-brain
barrier disruption. Int J Radiat Oncol Biol Phys 2005;62:279–87.
[34] Rola R, Raber J, Rizk A, Otsuka S, VandenBerg SR, Morhardt DR, et al. Radiation-
induced impairment of hippocampal neurogenesis is associated with cognitive
deficits in young mice. Exp Neurol 2004;188:316–30.
[35] Bianchi A, Dufort S, Lux F, Fortin PY, Tassali N, Tillement O, et al. Targeting and
in vivo imaging of non-small-cell lung cancer using nebulized multimodal
contrast agents. Proc Natl Acad Sci U S A 2014;111:9247–52.
[36] Caravan P, Ellison JJ, McMurry TJ, Lauffer RB. Gadolinium(III) chelates as MRI
contrast agents: structure, dynamics, and applications. Chem Rev
1999;99:2293–352.
[37] Sherry AD, Caravan P, Lenkinski RE. Primer on gadolinium chemistry. J Magn
Reson Imaging 2009;30:1240–8.eranostic gadolinium-based nanoparticles improve high-grade rat glioma
5.065
